| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Forte Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.44 |
| 52 Week High | US$0.90 |
| 52 Week Low | US$0.31 |
| Beta | 1.48 |
| 11 Month Change | -16.57% |
| 3 Month Change | -32.09% |
| 1 Year Change | -49.94% |
| 33 Year Change | -98.35% |
| 5 Year Change | n/a |
| Change since IPO | -97.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 37TA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.1% | 1.2% | 0.8% |
| 1Y | -49.9% | -16.0% | 6.1% |
Return vs Industry: 37TA underperformed the German Biotechs industry which returned -16% over the past year.
Return vs Market: 37TA underperformed the German Market which returned 6.1% over the past year.
Price Volatility
| 37TA volatility | |
|---|---|
| 37TA Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 37TA's share price has been volatile over the past 3 months.
Volatility Over Time: 37TA's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 11 | Paul A. Wagner | www.fortebiorx.com |
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Forte Biosciences, Inc. Fundamentals Summary
| 37TA fundamental statistics | |
|---|---|
| Market cap | €17.17m |
| Earnings (TTM) | -€29.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs 37TA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 37TA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$32.14m |
| Earnings | -US$32.14m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.88 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 37TA perform over the long term?
See historical performance and comparison